Nagamori S, Shinohara N, Kashiwagi A, Togashi M, Seki H, Toyota K, Harabayashi T, Nonomura K, Koyanagi T
Department of Urology, Sapporo National Hospital, Hokkaido Cancer Center, Japan.
Nihon Hinyokika Gakkai Zasshi. 1996 Apr;87(4):754-9. doi: 10.5980/jpnjurol1989.87.754.
Renal cell carcinomas (RCCs) develop in 8-63% of von Hippel-Lindau disease (VHL) patients, and loss of 3p segments, chromosome aberrations found in 90% of sporadic RCCs, has also been observed in RCCs associated with VHL. In fact, comparative analysis showed that the chromosome aberrations in RCCs associated with VHL are similar to those found in sporadic RCCs. VHL patients have the whole spectrum of tumors from small early lesions to large ones in the same kidney, providing a unique opportunity to analyze tumors in different stages of development. Subsequently deoxyribonucleic acid (DNA) content in RCCs of VHL patients was examined and correlated to their tumor size to gain some insight in the progression of sporadic RCCs.
From 1988 to 1991, we have experienced 6 cases of RCCs associated with VHL who underwent partial or radical nephrectomy. A total number of 52 paraffin-embedded samples from 33 RCCs from 6 patients with VHL was analyzed by flow cytometry.
The sizes of tumors ranged from 0.2 to 8.2 cm. DNA aneuploid patterns demonstrated in none of 9 tumors less than 1.6 cm, 4 of 14 tumors (29%) as large as 1.6 to 2.5 cm, and 5 of 10 tumors (50%) larger than 2.5 cm (p < 0.05). Twelve tumors less than 1.8 cm showed DNA diploid, so the smallest size of aneuploid tumors was 1.8 cm.
These data suggest that DNA ploidy change (diploid to aneuploid) in RCCs probably takes place as tumors grow approximately 1.8 cm in size.
8% - 63%的冯·希佩尔 - 林道病(VHL)患者会发生肾细胞癌(RCC),并且在90%的散发性肾细胞癌中发现的3p片段缺失及染色体畸变,在与VHL相关的肾细胞癌中也有观察到。事实上,对比分析表明,与VHL相关的肾细胞癌中的染色体畸变与散发性肾细胞癌中的相似。VHL患者在同一肾脏中会出现从小的早期病变到大型肿瘤的各种肿瘤,这为分析不同发育阶段的肿瘤提供了独特的机会。随后对VHL患者肾细胞癌中的脱氧核糖核酸(DNA)含量进行了检测,并将其与肿瘤大小相关联,以深入了解散发性肾细胞癌的进展情况。
1988年至1991年,我们诊治了6例与VHL相关的肾细胞癌患者,他们接受了部分或根治性肾切除术。通过流式细胞术分析了6例VHL患者33个肾细胞癌的52个石蜡包埋样本。
肿瘤大小从0.2厘米到8.2厘米不等。在9个小于1.6厘米的肿瘤中,无DNA非整倍体模式;在14个大小为1.6至2.5厘米的肿瘤中,有4个(29%)呈现DNA非整倍体模式;在10个大于2.5厘米的肿瘤中,有5个(50%)呈现DNA非整倍体模式(p < 0.05)。12个小于1.8厘米的肿瘤显示为DNA二倍体,因此非整倍体肿瘤的最小尺寸为1.8厘米。
这些数据表明,肾细胞癌中的DNA倍性变化(从二倍体到非整倍体)可能在肿瘤生长至约1.8厘米大小时发生。